SONY

Product Data Sheet

PE anti-human CD44 variant 9 (CD44v9)

Catalog # / Size: 2572015 / 25 tests
2572020 / 100 tests

Clone: RV3

Isotype: Rat IgG2a, κ

Immunogen: Human CD44v8-10 transfected cells

Reactivity: Human

Preparation: The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Workshop Number: IV T-186

Concentration: Lot-specific



PHA-stimulated (3 days) human peripheral blood lymphocytes were stained with CD44 isoform 9 (CD44v9) (clone RV3) PE (filled histogram) or Rat IgG2a, κ isotype control PE (open histogram).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Application Notes: Additional reported applications (for the relevant formats) include: immunohistochemical staining of frozen tissue sections[3].



Human peripheral blood lymphocytes were stained with anti-human CD56 (clone HCD56) APC and anti-human CD57 recombinant (clone QA17A04) Spark PLUS UV™ 395 (left) or mouse IgG1, κ Spark PLUS UV™ 395 isotype control (right).

Application References:

1. Kakehashi, A., *et al.* 2016. *Cancer Sci.* 107: 609. (IHC-P)
2. Aso T, *et al.* 2015. *PLoS One.* 10: e0116596. (IHC-P)
3. Yoshikawa M, *et al.* 2013. *Cancer Res.* 73: 1855. (IHC-F)
4. Ishimoto T, *et al.* 2011. *Cancer Cell.* 387-400. (IHC-P)

For research use only. Not for diagnostic use. Not for resale. Sony Biotechnology Inc. will not be held responsible for patent infringement or other violations that may occur with the use of our products.

Sony Biotechnology Inc. 1730 North First Street, San Jose, CA 95112 www.sonybiotechnology.com

Description: CD44 isoform 9, also known as CD44v9, is a CD44 isofom consisting of exons 1-5, 13 (v9) and 15 to 19, product of alternative splicing. CD44v9 is expressed by cancer stem cells, epithelial-type carcinomas, subsets of monocytes and subsets of lymphocytes; have a role in tumor initiation, maintenance and metastasis of cancer cells. CD44v9 interacts with the glutamate-cystine transporter xCT, increasing reduced glutathione and contributing to the ROS resistance of cancer cells, and is a potential predictive marker for recurrence of some cancers and a potential therapeutic target.

Antigen References:

1. Hagiwara M, et al. 2018. BMC Cancer. 18:113
2. Matsumoto T, et al. 2017. Oncogenesis. 6:397
3. Bertaux-Skeirik N, et al. 2017. J. Pathol. 242:463
4. Kodama H, et al. 2017. Br. J. Cancer. 116:186

For research use only. Not for diagnostic use. Not for resale. Sony Biotechnology Inc. will not be held responsible for patent infringement or other violations that may occur with the use of our products.